acoramidis
Cardiovascular system (C01)Cardiovascular system (C01) compound in BridgeBio Oncology Therapeutics's portfolio. Molecular target: Transthyretin.
- Target
- Transthyretin
- Mechanism
- Transthyretin stabiliser
pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
BridgeBio Oncology Therapeutics pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BridgeBio Oncology Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Transthyretin.
- Target
- Transthyretin
- Mechanism
- Transthyretin stabiliser
-
Development asset linked to BridgeBio Oncology Therapeutics in public FDA and regional records.
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BridgeBio Oncology Therapeutics's portfolio.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
infigratinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BridgeBio Oncology Therapeutics's portfolio. Molecular target: Fibroblast growth factor receptor.
- Target
- Fibroblast growth factor receptor
- Mechanism
- Fibroblast growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.
- Target
- Fibroblast growth factor receptor
- Mechanism
- Fibroblast growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to BridgeBio Oncology Therapeutics in public FDA and regional records.
-
Development asset linked to BridgeBio Oncology Therapeutics in public FDA and regional records.
-
Development asset linked to BridgeBio Oncology Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist